EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox

Sara Moufarrij, Roisin E O'Cearbhaill iD

Current Oncology · 23.12.2023 · 31 (1) · 97-114

DOI: 10.3390/curroncol31010007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 23.12.2023. Verfasst von Sara Moufarrij und 1 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Ovarian Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite high response rates to initial therapy, most patients with ovarian cancer will ultimately recur and go on to develop resistance to standard treatments. Novel therapies have been developed to overcome drug resistance and alter the tumor immune microenvironment by targeting oncogenic pathways, activating the innate immune response, and enhancing drug delivery. In this review, we discuss the current and future roles of chemotherapy, targeted agents such as poly (ADP-ribose) polymerase (PARP) inhibitors, bevacizumab, and mirvetuximab in the treatment of ovarian cancer. We explore the emerging role of therapeutic targets, including DNA repair pathway inhibitors and novel antibody–drug conjugates. Furthermore, we delve into the role of immunotherapeutic agents such as interleukins as well as immune-promoting agents such as oncolytic viruses and cancer vaccines. Innovative combination therapies using these agents have led to a rapidly evolving treatment landscape and promising results for patients with recurrent ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalOvarian NeoplasmsHumansFemaleCarcinoma, Ovarian EpithelialBevacizumabTherapies, InvestigationalTumor Microenvironment

Stichwörter der Autor:innen

antibody–drug conjugatecheckpoint inhibitionhomologous recombination deficiencymonoclonal antibodynanoparticleoncolytic virusesovarian cancerpoly (ADP-ribose) polymerase inhibitionresistancevaccines

Substanzen

Bevacizumab

Autor:innen und Institutionen

  • Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.

ORCID-Profile: Roisin E O'Cearbhaill

Förderung

  • NCI NIH HHS
  • Cancer Center

Zitieren

APA

Moufarrij, S., & O'Cearbhaill, R. E. (2023). Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox. Current Oncology, 31(1), 97-114. https://doi.org/10.3390/curroncol31010007

Vancouver

Moufarrij S, O'Cearbhaill RE. Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox. Current Oncology. 2023;31(1):97-114. doi:10.3390/curroncol31010007

BibTeX
@article{Moufarrij2023,
  author = {Moufarrij, Sara and O'Cearbhaill, Roisin E},
  title = {Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox},
  journal = {Current Oncology},
  year = {2023},
  volume = {31},
  number = {1},
  pages = {97--114},
  doi = {10.3390/curroncol31010007}
}
Kostenlos starten →